Literature DB >> 10470201

The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.

G M Oremek1, S Teigelkamp, W Kramer, E Eigenbrodt, K H Usadel.   

Abstract

Various isoforms of the glycolytic enzyme pyruvate kinase are expressed in different cell-types. One of these isoforms, the type Tu M2-PK, is strongly overexpressed by tumor cells and released into body fluids. The concentration of Tu M2-PK in body fluids can be quantitatively determined by a commercially available enzyme-linked immunosorbent assay (ELISA)-kit. Using this kit, the Tu M2-PK concentration was measured in EDTA-plasma of 64 patients with renal carcinoma and 10 patients suffering from nephritis. The ranges of the Tu M2-PK-concentrations of the two groups did not overlap, indicating a highly significant discrimination of renal carcinoma and benign renal diseases. Furthermore, the Tu M2-PK-concentration in EDTA-plasma correlates strongly with the Robson tumor stage of the 64 patients. The present results indicate that the Tu M2-PK might be the first tumor marker which could be an excellent complementation of the diagnostic program for renal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10470201

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK.

Authors:  Carolin Tonus; Gero Neupert; Markus Sellinger
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

2.  Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma.

Authors:  J Roigas; S Deger; J Schroeder; A Wille; I Turk; B Brux; K Jung; D Schnorr; S A Loening
Journal:  Urol Res       Date:  2003-09-26

3.  Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.

Authors:  Maurizio Ventrucci; Antonio Cipolla; Chiara Racchini; Riccardo Casadei; Patrizia Simoni; Lucio Gullo
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

4.  Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls.

Authors:  Bo Zhang; Jian-Ying Chen; Dao-Da Chen; Guo-Bin Wang; Ping Shen
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

5.  Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis.

Authors:  Zhimin Lu
Journal:  Chin J Cancer       Date:  2011-12-23

6.  The value of expression of M2-PK and VEGF in patients with advanced gastric cancer.

Authors:  Lanning Yin; Xiang Wang; Changjiang Luo; Haipeng Liu; Ling Zhang; Hong Zhang; Youcheng Zhang
Journal:  Cell Biochem Biophys       Date:  2013       Impact factor: 2.194

7.  Expression of p-AKT characterizes adenoid cystic carcinomas of head and neck with a higher risk for tumor relapses.

Authors:  Hans-Ullrich Völker; Matthias Scheich; Annette Berndt; Imme Haubitz; Alexandra Metzger; Hans-Konrad Müller-Hermelink; Ulrike Kämmerer; Melanie Schmidt
Journal:  Diagn Pathol       Date:  2009-06-19       Impact factor: 2.644

Review 8.  Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio.

Authors:  Marike W van Gisbergen; Emma Zwilling; Ludwig J Dubois
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

9.  PKM2, a Central Point of Regulation in Cancer Metabolism.

Authors:  Nicholas Wong; Jason De Melo; Damu Tang
Journal:  Int J Cell Biol       Date:  2013-02-14

10.  Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer.

Authors:  P D Hardt; S Mazurek; M Toepler; P Schlierbach; R G Bretzel; E Eigenbrodt; H U Kloer
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.